TABLE 2.
Whole-genome sequencing data from FOS-evolved HOU503 isolates
| Isolate | MIC (μg/mL)a |
Mutation(s) inb: |
Additional mutationsb,c | ||
|---|---|---|---|---|---|
| DAP | FOS | pyk | MurAB | ||
| FT1 | |||||
| F1 | 5.3 | >1,024 | G135S | −73 | +4 |
| F2 | 4 | >1,024 | K165R | −73 | +3 |
| F3 | 8 | >3,584 | P330L | −73 | +2 |
| F4 | 4 | >1,024 | P12S | −73 | +4 |
| F5 | 5.3 | >1,024 | G162R | −73 | +3 |
| F6 | 4 | >1,024 | P330L | −73 | +5 |
| F7 | 6.7 | >1,024 | P266A | Insertion upstream | +2 |
| F8 | 5.3 | >1,024 | P266A | Insertion upstream | +2 |
| F9 | 4 | >1,024 | P266A | Insertion upstream | +2 |
| F10 | 6.7 | >1,024 | M289I | −73 | +4 |
| F11 | 6.7 | >1,024 | M289I | −73 | +4 |
| F12 | 5.3 | >1,024 | M289I | −73 | +4 |
| F13 | 12 | 512 | −73 | +4 | |
| F14 | 10.7 | 597.3 | −73 | +3 | |
| F15 | 5.3 | 768 | −73 | +3 | |
| FT2 | |||||
| F16 | 4 | >3,584 | L264P | −73 | +2 |
| F17 | 4 | 512 | −73 | +3 | |
| F18 | 4 | >1,024 | G257S | −73 | +5 |
| F19 | 4 | >1,024 | M319I | −73 | +4 |
| F20 | 13.3 | >1,024 | G235R | −73 | +3 |
| F21 | 13.3 | >1,024 | G235R | −73 | +4 |
| F22 | 2.7 | >1,024 | M256I | −73 | +3 |
| F23 | 4 | >1,024 | R298L | −73 | +2 |
| F24 | 8 | >1,024 | R298L | −73 | +3 |
| F25 | 8 | >1,024 | R298L | −73 | +2 |
| F26 | 4 | >1,024 | M289I | −73 | +5 |
| F27 | 4 | >1,024 | E303G | −73 | +2 |
| F28 | 5.3 | >1,024 | P297R | −73 | +3 |
a
The MICs reported were averaged over three biological replicates. The HOU503 (LiaRW73C LiaST120A) DAP MIC was 3 μg/mL, and the FOS MIC was 128 μg/mL.
b
The selected mutations shown do not include those observed in the no-drug control isolates or the initial starting ancestor. Two isolates were not included due to contamination issues.
c
The “Additional mutations” column includes occurrences of van operon (vanRSHAXYZ) loss. All isolates lost both van operon copies.